A Promising Regimen for Extranodal NK/T-Cell Lymphoma?

Patients who received concurrent chemoradiotherapy followed by combination chemotherapy achieved high response rates and durable remissions.

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is an aggressive Epstein-Barr virus–associated non-Hodgkin lymphoma that is more prevalent in Asia than in Western countries. Many patients — even those who present with localized disease and undergo intensive radiation therapy plus anthracycline-based chemotherapy — experience early relapse and death from local and systemic disease progression.

To test the efficacy and safety of using concurrent chemoradiotherapy (CCRT) followed by systemic chemotherapy in this setting, investigators conducted a phase II trial in which 30 patients (median age, 48.5) with localized ENKTL (15 had stage IE disease; 15 had stage IIE disease) were treated concurrently with weekly cisplatin (30 m…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee